Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Dose-Response Relationship: Overview01:03

Dose-Response Relationship: Overview

4.6K
Agonists can bind with and activate receptors, resulting in the formation of drug-receptor complexes. Once formed, these complexes catalyze many biochemical processes at the cellular level and subsequently induce a pharmacologic response. The degree of response is directly proportional to the fraction of activated receptors, which in turn, depends on the concentration of the drug at the receptor site as well as the sensitivity of the receptor. An increase in the administered dose contributes to...
4.6K
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

199
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
199
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

104
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
104
Dose-Response Relationship: Potency and Efficacy01:22

Dose-Response Relationship: Potency and Efficacy

6.2K
The potency of a drug is the measure of its ability to produce a biological response and can be compared by looking at the half-maximum effective concentration or EC50 values of different drugs. A lower EC50 value indicates higher potency of the drug. In the dose–response curve of two antihypertensive drugs, candesartan and irbesartan, a significant difference is observed in their EC50 values. A lower EC50 value for candesartan indicates that it is more potent than irbesartan, as it...
6.2K
Dosage Regimen: Individualization01:24

Dosage Regimen: Individualization

124
Individualization in dosing regimens is the customization of medication doses for individual patients. Its necessity arises from the goal of maximizing therapeutic benefits while minimizing risks. This approach is pivotal because human responses to drugs can vary widely; what is effective for one person may be inadequate or excessive for another. Interpatient (intersubject) variability refers to differences in drug responses between individuals, while intrapatient (intrasubject) variability...
124
Dose-Response Relationship: Selectivity and Specificity01:25

Dose-Response Relationship: Selectivity and Specificity

9.4K
Drugs exert their therapeutic effects by interacting with receptors, enzymes, or ion channels that are present throughout the human body. The strength and duration of the interaction between a drug and its target receptor are characterized by the selectivity and specificity of the drug. Selectivity refers to a drug's strong preference for its intended target over other targets. For instance, isoprenaline, a non-selective β-adrenergic agonist, interacts with both β1- and...
9.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Open Letter to the Health Physics Society Membership.

Health physics·2023
Same author

How the Science of Radiation Biology Can Help Reduce the Crippling Fear of Low-level Radiation.

Health physics·2023
Same author

Radiobiology of Select Radionuclides in Hanford Site Tank Waste.

Health physics·2022
Same author

Welcoming Session.

Health physics·2020
Same author

Opening Session.

Health physics·2020
Same author

Dose-response Relationships in the Context of Standards for Radiation Protection.

Health physics·2020
Same journal

Assessment of Health Risks of Adults and Children Due to Consumption of Uranium in Groundwater from Chengalpattu District, Tamil Nadu, India.

Health physics·2026
Same journal

Radiation Protection Abstracts, Volume 46, Number 1.

Health physics·2026
Same journal

Specialized Radiological Assets for Navigable Two-dimensional and Three-dimensional Virtual and Augmented Reality.

Health physics·2026
Same journal

DoseBusters: A Fully Immersive Virtual Reality Game for Radiation Protection and Detection.

Health physics·2026
Same journal

Radioactivity in Bottled Drinking Water from Greater Dhaka City and Concomitant Ingestion Doses to Consumers.

Health physics·2026
Same journal

Assessment of Radiation Dose and Protection Practices in Neonatal Radiography in NICUs.

Health physics·2026
See all related articles

Related Experiment Video

Updated: Dec 29, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.0K

Can Regulators Accommodate an Alternative Dose-Response Paradigm?

Wayne M Glines1

  • 1HPS, 2315 Camas Avenue, Richland, WA 99354-1968; wglines34@charter.net.

Health Physics
|January 29, 2020
PubMed
Summary

No abstract available in PubMed .

More Related Videos

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.5K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

862

Related Experiment Videos

Last Updated: Dec 29, 2025

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays
06:13

Stepwise Dosing Protocol for Increased Throughput in Label-Free Impedance-Based GPCR Assays

Published on: February 21, 2020

7.0K
Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay
09:03

Parallel Interrogation of β-Arrestin2 Recruitment for Ligand Screening on a GPCR-Wide Scale using PRESTO-Tango Assay

Published on: March 10, 2020

13.5K
Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control
07:13

Author Spotlight: Developing Parmodulins to Target Protease-Activated Receptors for Inflammation Control

Published on: May 24, 2024

862